|
IP6K1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.79700000049843E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.75580000003362E-06 |
| Normal-vs-Stage2 |
1.070240E-02 |
| Normal-vs-Stage3 |
1.49859999964974E-07 |
| Normal-vs-Stage4 |
2.10649999999868E-05 |
| Stage1-vs-Stage2 |
3.014000E-01 |
| Stage1-vs-Stage3 |
1.242970E-01 |
| Stage1-vs-Stage4 |
2.692000E-01 |
| Stage2-vs-Stage3 |
3.936000E-02 |
| Stage2-vs-Stage4 |
8.585600E-02 |
| Stage3-vs-Stage4 |
9.655600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.48520000023511E-07 |
| Normal-vs-AfricanAmerican |
5.167900E-02 |
| Normal-vs-Asian |
3.322800E-03 |
| Caucasian-vs-AfricanAmerican |
1.710240E-01 |
| Caucasian-vs-Asian |
2.336600E-01 |
| AfricanAmerican-vs-Asian |
6.407800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.64378999999437E-05 |
| Normal-vs-Female |
5.63269999975802E-07 |
| Male-vs-Female |
8.418000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.88710000000159E-05 |
| Normal-vs-Age(41-60Yrs) |
2.90759999999057E-06 |
| Normal-vs-Age(61-80Yrs) |
1.43590000001304E-06 |
| Normal-vs-Age(81-100Yrs) |
9.063700E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.200400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.194400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.456400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.777800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.057200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.193000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.57350000000012E-05 |
| Classical-VS-Follicular |
1.459580E-02 |
| Classical-VS-Other |
1.645610E-01 |
| Classical-VS-Normal |
8.0893999999998E-05 |
| Tall-VS-Follicular |
9.313600E-02 |
| Tall-VS-Other |
8.865000E-01 |
| Tall-VS-Normal |
1.06330000360089E-08 |
| Follicular-VS-Other |
5.998800E-01 |
| Follicular-VS-Normal |
1.48320000004087E-06 |
| Other-VS-Normal |
1.090350E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.72309999996379E-06 |
| Normal-vs-N1 |
4.38699999993908E-07 |
| N0-vs-N1 |
3.885600E-02 |
|
|
